Introduction
Uncontrolled Wnt signaling is a hallmark of several types of cancer (Polakis, 2007) . In human colon cancer, the deregulation of the Wnt/b-catenin (canonical) pathway through mutations in the tumour (T) suppressor gene adenomatous polyposis coli or, less frequently, in CTNNB1/b-catenin or AXIN1, underpins the early stages of tumourigenesis (Segditsas and Tomlinson, 2006) . The Wnts comprise a large family of protein ligands that affect several developmental processes and play a key role in the maintenance of stem cell pluripotency during adult homeostasis (Logan and Nusse, 2004) . In canonical Wnt signaling, Wnt binding to frizzled and low density lipoprotein receptor-related protein (LRP5/6) coreceptors induces b-catenin protein stabilization and entry to the nucleus, where b-catenin binds lymphoid enhancer factor/T-cell factor (LEF/ TCF) transcription factors and affects the transcription of target genes, many of which are involved in cell proliferation and invasion (Logan and Nusse, 2004) .
Wnt reception is modulated by secreted extracellular Wnt antagonists, which can be divided into two functional classes: those that bind directly to Wnts (secreted frizzled related proteins (SFRPs), Wnt inhibitory factor-1 and Xenopus cerberus), thereby altering their ability to bind to the Wnt receptor complex; and those that inhibit Wnt signaling by binding to the LRP5/ 6 component of the Wnt receptor complex (certain Dickkopf (DKK) family proteins, and Wise) (Kawano and Kypta, 2003) . The DKK family encodes secreted proteins of 255-350 amino acids and consists of four main members in vertebrates (DKK-1 to -4) (Niehrs, 2006) . DKK-1, the most widely studied member of this family and DKK-4 act as pure inhibitors of Wnt/ b-catenin signaling. In contrast, DKK-2 can activate or inhibit the pathway, depending on cellular context, while DKK-3 can neither bind LRP5/6 nor affect Wnt signaling (Niehrs, 2006) .
To date, DKK-4 is the least studied and characterized member of the DKK family. The expression pattern of DKK-4 is unclear. Northern analysis of several adult and fetal human tissues did not detect DKK-4 messenger RNA (mRNA), although a survey of a human cDNA library panel by PCR with specific primers generated products from libraries prepared from cerebellum, activated human T-lymphocytes, lung and esophagus (Krupnik et al., 1999) . Murine DKK-4 mRNA is localized to the preplacodes at sites of presumptive epithelial-mesenchymal interactions during appendage morphogenesis, including the dental lamina, mammary gland, eccrine gland and primary and secondary hair follicles (Bazzi et al., 2007) .
In this study, we report that the human DKK-4 gene is inhibited by 1a,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ), the most active metabolite of vitamin D, in colon cancer cells. Expression of DKK-4 was upregulated in a series of 29 human colorectal Ts as compared with control normal (N) tissue. There is an inverse correlation between the expression of DKK-4 and that of the vitamin D receptor (VDR), and we demonstrate that DKK-4 is a downstream target of TCF/b-catenin complexes. Our data show that DKK-4 is upregulated in human colon cancer and that its overexpression is associated with the acquisition of migratory, invasive and proangiogenic properties by neoplastic cells. In this context, downregulation of DKK-4 is a novel action of 1,25(OH) 2 D 3 that may contribute to the protection of colon epithelial cells from malignant transformation.
Results
DKK-4 is repressed by 1,25(OH) 2 D 3 in human colon cancer cells A recent transcriptome analysis designed to identify 1,25(OH) 2 D 3 target genes in human SW480-ADH colon cancer cells revealed a 27.3-fold decrease in DKK-4 mRNA following a 2-day 1,25(OH) 2 D 3 treatment. We used quantitative RT-PCR to validate these data. Time course experiments showed that 1,25(OH) 2 D 3 (10 À7 M) caused a rapid inhibition (30%) of DKK-4 mRNA at 4 h post treatment, which was enhanced (>90%) at 48 h ( Figure 1a) . DKK-4 downregulation was dose dependent, with 50% inhibition observed at 10 À9 M 1,25(OH) 2 D 3 (Figure 1b ). Variable inhibition of DKK-4 mRNA expression by 1,25(OH) 2 D 3 was also found in certain human colon cancer cell lines (Caco-2, HCT116) ( Figure 1c ). The repression of DKK-4 was confirmed at the protein level ( Figure 1d , and Supplementary Material Figure 1 ).
To examine whether 1,25(OH) 2 D 3 altered DKK-4 transcription, we cloned a 1.56 kb fragment of the human DKK-4 promoter. This promoter was significantly inhibited in SW480-ADH colon cancer cells and also in several breast cancer cell lines (MCF-7, MDA-MB-468 and MDA-MB-453) (Figure 2a ). In accordance with transcriptional repression, the cotransfection of VDR-negative human embryonic kidney (HEK)-293T cells with a wild-type VDR allowed inhibition of the DKK-4 promoter by 1,25(OH) 2 D 3 (Figure 2b ). Inhibition did not occur with mutant versions that lacked either the capacity to bind DNA (K45E-VDR) or the carboxy-terminal AF-2 region responsible for transcriptional activation (DAF2-VDR).
The sequence analysis of the DKK-4 gene promoter (NCBI database) revealed two putative conserved VDRbinding sites near the TSS, each with one deviation from a consensus-binding motif: a direct repeat with three nucleotide spacers (DR3) conserved in mouse, rat and DICKKOPF-4 in human colon cancer N Pendás-Franco et al dog, and an everted repeat with six nucleotide spacers (ER6) conserved in dog located respectively at positions À687/À673 and À159/À141 relative to the TSS (Figure 2c ). With one exception, putative VDR elements located further away from the TSS were not conserved and these sites did not contain consensus-binding motifs. This indicates that the proximal binding sites most likely mediate the responsiveness of the DKK-4 gene, which is consistent with the data from the reporter gene assays. To assess the functionality of these sites, we performed ChIP assays using specific primers for both promoter regions and also for a separate region (À1218/ À928) as a negative control. 
DKK-4 is a downstream target of TCF/b-catenin
Sequence analysis of the DKK-4 promoter revealed five putative TCF-binding sites ( Figure 2c ). As the Wnt/ b-catenin canonical pathway is constitutively activated in most human colon Ts, a plausible explanation for the observed upregulation of DKK-4 is its control by TCF/ b-catenin. To test this hypothesis, we analyzed the ability of TCF4-VP16, a constitutively active version of TCF4, to induce the transcription of the DKK-4 promoter. To avoid the endogenous activation of the Wnt/b-catenin pathway in colon cancer cells, we used human breast cancer cells. In MCF-7 cells, TCF4-VP16 caused a dose-dependent activation of the DKK-4 gene promoter that was comparable to, but lower, than that with lithium, a well-known inhibitor of GSK3b and activator of the pathway, led to a 13-fold induction in DKK-4 expression ( Figure 4d , right panel). These results support the hypothesis that DKK-4 overexpression in colon cancer is, at least in part, due to the activation of Wnt canonical signaling.
Ectopic expression of DKK-4 affects the morphology and the migratory, invasive and angiogenic potential of human colon cancer cells We assessed whether DKK-4 upregulation in human colon cancer is a side effect of aberrant Wnt/b-catenin activation or whether it has functional implications for Figure 4) . First, we analyzed the effect of DKK-4 expression on cell morphology. While that of SW480-ADH cells was not substantially affected by the transgene, DKK-4-expressing DLD-1 cells became more elongated and showed less intercellular adhesion (Figure 5a ). Expression of the transgene did not influence either the rate of proliferation or the survival of SW480-ADH or DLD-1 cells in serum-free medium (data not shown). However, unexpectedly, DKK-4 increased the migration of SW480-ADH and, to a greater extent, DLD-1 cells in vitro (Figure 5b ). To confirm this result, we studied the ability of a DKK-4 siRNA to inhibit the migration of SW480-ADH cells. The 50% decrease in the endogenous level of DKK-4 RNA achieved by this procedure (Supplementary Material Figure 5 ) led to a significant reduction in cell migration (Figure 5c ). Likewise, DKK-4 enhanced the invasive capacity of SW480-ADH and DLD-1 cells in Matrigel-based assays (Figure 5d ).
To test whether DKK-4 affects the angiogenic potential of colon cancer cells, we collected CM from SW480-ADH and DLD-1 cells transfected with empty vector or the DKK-4 cDNA. CM from cells expressing DKK-4 caused a significant dose-dependent increase in Figure 6 ). Additionally, we studied the formation of capillary-like tubules by HMVEC in vitro using growth factor-reduced Matrigel. Our results showed that CM from both control and DKK-4-expressing cells similarly induced tubule formation after 4 h ( Figure 6c , middle panels). However, when using suboptimal conditions (diluted 1:2 (v/v) Matrigel: medium), only the CM from DKK-4-expressing cells increased the morphogenetic capacity of HMVEC after 48 h incubation (Figure 6c , bottom panels).
Discussion
Here, we show that DKK-4 is upregulated in human colon cancer and its overexpression enhances the migratory, invasive and proangiogenic potential of cultured colon cancer cells. Thus, although DKK-4 can act as a Wnt inhibitor (Mao and Niehrs, 2003) , our data support a new role for this protein in human colon cancer. In line with our findings, the expression of the SFRP1 and SFRP2 Wnt inhibitors is upregulated in glioma-derived cell lines and SFRP2 promotes T growth in nude mice (Roth et al., 2000) . Moreover, SFRP4 is expressed in the stromal cells surrounding endometrial and breast carcinomas but is barely detectable in the stroma of secretory or menstrual endometrium (Abu-Jawdeh et al., 1999). Additionally, SFRP1 induces angiogenesis in chick chorioallantoic membranes and increases migration and organization of endothelial cells into capillary-like structures (Dufourcq et al., 2002) . Thus, upregulation of DKK-4 and other Wnt inhibitors in cancer cells implicates them in other roles than the control of this signaling pathway. The finding that DKK-4 is induced by TCF/b-catenin may explain the upregulation of this gene in colon Ts. Transcriptional activation of the human DKK-4 promoter by canonical Wnt signaling creates a negative feedback loop similar to that described for DKK-1 (Gonzalez- . In line with our data, it has been reported that the murine DKK-4 promoter is upregulated by TCF/b-catenin (Sick et al., 2006; Bazzi et al., 2007) and that TCF/b-catenin complexes also bind in vivo to the human promoter (Bazzi et al., 2007) . Unlike DKK-1, whose expression is lost in colorectal cancer despite constitutive Wnt/b-catenin activation (Gonzalez-Sancho et al., 2005; Aguilera et al., 2006), the DKK-4 autoregulatory mechanism seems to remain fully active in this neoplasia, as DKK-4 is upregulated in human colon Ts and its transcription is inhibited by a dominant negative TCF4 in cultured colon cancer cells. Confirming our results, in a recent study, the expression of DKK-4 was completely undetectable in 10 of 24 N human colon tissue samples, while the remaining 14 N samples also had eightfold lower expression of DKK-4 compared with Ts (Xi et al., 2008 ) DKK-4 overexpression in colorectal Ts may be either a side effect of constitutive Wnt/b-catenin activation or a defense mechanism to excessive canonical signaling. However, the effect of DKK-4 on colon cancer cell phenotype, migration, invasion and angiogenic potential indicates that it may induce b-catenin-independent actions during the progression of this neoplasia. To our knowledge, this is the first time that DKK-4 has been associated with regulation of cell migration. In this regard, DKK-1 has been proposed to modulate gastrulation movements by coordinated modulation of the Wnt/b-catenin and Wnt/planar cell polarity pathways (Caneparo et al., 2007) and to act as an attractive guidance cue controlling the directional migration of visceral endoderm cells (Kimura-Yoshida et al., 2005) . Our data show that DKK-1-and DKK-4-enriched CM have opposite effects on HMVEC migration. Both DKK-4-enriched CM and recombinant DKK-4 protein increase cell migration, while DKK-1-enriched CM reduces it. This result suggests that either DKK-4 induces the secretion of migration-promoting factors or that DKK-4 is a migration-inducing factor itself.
We also present evidence that the pleiotropic hormone 1,25(OH) 2 D 3 inhibits the expression of DKK-4 mRNA and protein in human colon cancer cells. The inverse correlation between VDR and DKK-4 mRNA levels in human colorectal Ts suggests that this regulation also occurs in patients. 1,25(OH) 2 D 3 has broad anti-T effects in many types of cancer cells (Ordonez-Moran et al., 2005) . Previous studies by our group have revealed that 1,25(OH) 2 D 3 antagonizes the Wnt/b-catenin signaling pathway by promoting: (a) the binding of VDR to b-catenin, thus preventing the formation of transcriptionally active TCF/b-catenin complexes; (b) the activation of CDH1/E-cadherin transcription, which favours the nuclear export of b-catenin and its relocalization bound to E-cadherin at the plasma membrane adherens junctions (Palmer et al., 2001) and (c) the induction of the DKK-1 gene . As DKK-4 is a TCF/b-catenin target gene, our data support that 1,25(OH) 2 D 3 inhibits its expression by two mechanisms: (a) by direct binding of VDR to the DKK-4 promoter and (b) indirectly through the TCF/b-catenin-binding sites. The additive effect of 1,25(OH) 2 D 3 and DN-TCF4 on DKK-4 expression suggests that the negative effect of the hormone on the TCF/b-catenin-binding sites does not accomplish for its full inhibitory action.
While 1,25(OH) 2 D 3 -mediated DKK-1 accumulation is slow and requires intermediate proteins , DKK-4 downregulation occurs rapidly and with VDR binding directly to the gene promoter region.
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Thus, the regulation and expression of DKK-1 and DKK-4 follow opposite directions in human colorectal cancer. While they both behave as antagonists, DKK-4 is less potent than DKK-1 in inhibiting Wnt/b-catenin signaling and its activity is largely dependent on high Kremen2 expression levels (Mao and Niehrs, 2003 , and our unpublished results). Moreover, the b-cateninindependent activities of the two proteins differ markedly. Thus, DKK-1 seems to have anti-tumoural effects independently of the antagonism of TCF/b-catenin transcriptional activity in vitro and in vivo (Aguilera et al., 2006) . In contrast, the effects of DKK-4 on the phenotype of colon cancer cells and its upregulation in colon cancer (but not in breast) suggest T promoting actions. Therefore, inhibition of Wnt/b-catenin signaling appears to be just one of a series of mechanisms induced by DKK family proteins. Moreover, Wnt antagonism may not be the main mode of action for some members, such as DKK-4, in particular contexts.
In conclusion, our results show that DKK-4 is a new TCF/b-catenin target gene that is upregulated in human colon cancer where it affects the migratory, invasive and angiogenic phenotype of colon cancer cells, most likely through b-catenin-independent mechanisms. 1,25(OH) 2 D 3 is a potent inhibitor of DKK-4 expression and further studies should determine the importance of this effect for the complex anti-cancer activity of this hormone.
Materials and methods
Cell culture, conditioned media Human colon and breast cancer cells were cultivated as reported (Palmer et al., 2001; Pendas-Franco et al., 2007) . Primary human microvascular endothelial cells (HMVEC) were grown in MCDB 131 medium (Sigma, St. Louis, MO, USA) supplemented with 10% fetal calf serum and 2 mM L-glutamine (Invitrogen, Paisley, UK), 10 ng/ml epidermal growth factor (Peprotech, London, UK), 10 ng/ml hydrocortisone (Sigma) and 16.32 mg/ml bovine pituitary extract (Invitrogen) . All experiments using 1,25(OH) 2 D 3 were performed using charcoal-treated fetal calf serum. To obtain conditioned media (CM), cells were grown to 80% confluence and then incubated in serum-free medium for 48 h. CM were harvested, centrifuged for 10 min at 2000 g, and concentrated 100-fold using Amicon Ultra-15 and Microcon YM-10 columns (Millipore Corporation, Bedford, MA, USA). To generate DKK-4-expressing lines, SW480-ADH and DLD-1 cells were transfected with either pcDNA3-HA or pcDNA3-DKK-4-HA. Stable transfectants were obtained after selection with 600 mg/ ml G418 (Sigma) for 2 weeks and DKK-4 expression was assessed by western blotting. Constructs A 1.56 kb fragment of the DKK-4 promoter (-1496/ þ 63) was amplified by PCR using genomic DNA from SW480-ADH cells as template, and primers: 5 0 -AGGAAGCAGAGAA ACCCGGC-3 0 and 5 0 -AGCGAGGCTGCTCTCCACCC-3 0 . The resulting product was cloned into the pCRII-TOPO vector (Invitrogen) and sequenced. Subsequently, it was subcloned as a KpnI/XhoI fragment into the promotorless pGL3basic Firefly luciferase expression vector (Promega, Madison, WI, USA). To generate pcDNA3-DKK4-HA, the DKK-4 open reading frame was amplified by reverse transcriptase-PCR (RT-PCR) using RNA from SW480-ADH cells as template and primers: 5 0 -GAGGATCCATGGTGGCGG CCGTCCTG-3 0 and 5 0 -ACGATATCCTAGCTTTTCTATT TTTTG-3 0 . The resulting 675 bp product was cloned into pCRII-TOPO, sequenced and then, subcloned as a BamHI/ EcoRV fragment into pcDNA3-HA.
Western blotting
Whole cell extracts were prepared and analyzed as reported (Palmer et al., 2001; Pendas-Franco et al., 2007) . We used a rabbit anti-human DKK-4 polyclonal antibody generated at Sigma-Genosys (Haverhill, UK) using the peptide CPKRKPSIKKSQGR mouse monoclonal antibodies against the hemaglutinin epitope (HA, Babco, Richmond, CA, USA) and lamin B (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and a goat polyclonal antibody against b-actin (Santa Cruz). Secondary antibodies used were HPR-conjugated, anti-
Reporter assays Cells were transfected using the jetPEI transfection reagent (PolyPlus Transfection, Illkirch, France) and harvested 48 h later. Firefly and Renilla luciferase activities were measured separately using the Dual luciferase reagent kit (Promega) and a Lumat LB9507 luminometer (Berthold, Bad Wildbad, Germany).
In silico screening of putative VDR-and TCF-binding sites The sequence surrounding the transcription start site (TSS) of the DKK-4 gene was extracted from the NCBI database. A region spanning 10 kb up-and downstream of the TSS was analyzed for putative VDR-Retinoid-X receptor (RXR) heterodimer-binding sites. The effect of single nucleotide variations (Wang et al., 2005) in the consensus-binding motif suggested the following consensus motifs for the heterodimeric partners: RGKTCA for RXR and RRKDCA for VDR, when all variations binding 100% or more were included in the consensus motif (R ¼ A/G, K ¼ G/T and D ¼ A/G/T). We screened DR3-, DR4-and ER6-to ER9-type motifs from this region fitting the consensus or having at most one deviation from the consensus. In parallel, the conservation of putative sites was checked in multiple species using the UCSC Genome Browser (in the mouse, rat and dog genome). Putative TCF/bcatenin-binding sites in the proximal promoter region were predicted by Matinspector computer software (Genomatix, Ann Arbor, MI, USA).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were carried out as reported (Ballestar et al., 2003) using specific DKK-4 or CYP24 primers: DR3, 5 0 -TCATTGTTcCCACCATTGAA-3 0 (forward) and 5 0 -GAA GCTGTAAACTGGGCTTCA-3 0 (reverse); ER6, 5 0 -ATTGA ACCCCTGGAGGAGAA-3 0 (forward) and 5 0 -GCACGT CGTCTGTTTGTCAC-3 0 (reverse); negative control, 5 0 -TTG AGAATGTTCCCATGCAC-3 0 (forward) and 5 0 -TGCTT CATCCCTTTCCTGTC-3 0 (reverse); CYP24, 5 0 -CGTTTCCT CCTGTCCCTCTC-3 0 (forward) and 5 0 -TGCCTTCCTGGG GGTTATCTC-3 0 (reverse). Antibodies against VDR, SMRT (Santa Cruz) and histone H4 (acetyl K12) (Upstate, Lake Placid, NY, USA) and rabbit IgG (Santa Cruz) were used. The sensitivity of PCR amplification was evaluated on serial DICKKOPF-4 in human colon cancer N Pendás-Franco et al dilutions of total DNA collected after sonication (input fraction).
Patients, samples and RNA extraction All patients gave written informed consent and the protocol was approved by the Research Ethics Board of our Hospital Universitario Puerta de Hierro, Madrid. N and T tissue samples were obtained immediately after surgery, immersed in RNA later (Ambion; Applied Biosystems, Warrington, UK), snap frozen in liquid nitrogen and stored at À80 1C until processing. Tissue RNA was extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany).
Real-time RT-PCR
Real-time RT-PCR was performed as reported (GonzalezSancho et al., 2005) using the following primers: DKK-4, 5 0 -TGGACTTCAACAACATCAGGAG-3 0 (forward) and 5 0 -GGTATTGCAGTCCGTGTCAG-3 0 (reverse); VDR, 5 0 -TT GCCATACTGCTGGACGC-3 0 (forward) and 5 0 -GGCTC CCTCCACCATCATT-3 0 (reverse). Primers for DKK-1 were described previously . Values were normalized versus the geometric average of two control housekeeping genes (succinate dehydrogenase complex subunit A and ubiquitin C) as reported (Vandesompele et al., 2002) using the following primers: succinate dehydrogenase complex subunit-A, 5 0 -TGGGAACAAGAGGGCATCTG-3 0 and 5 0 -CCACCACTGCATCAAATTCATG-3 0 ; ubiquitin C, 5 0 -ATT TGGGTCGCGGTTCTTG-3 0 and 5 0 -TGCCTTGACATTCT CGATGGT-3 0 . As DKK-4 mRNA was not detected in N colon tissue, its expression was measured in a relative quantification only in those T tissue samples in which it was detected.
Data analysis
The T/N ratios of VDR gene expression and the expression of DKK-4 in T tissue were not normally distributed (KolmogorovSmirnov test, Lilliefors correction). For this reason, we normalized the data distribution by using log 10 for statistical analysis.
We also used the geometric (rather than the arithmetic) average of the (T/N) to describe the expression gene data. The correlations between gene expression levels were studied using the Pearson correlation coefficient.
Immunofluorescence Cells were fixed, permeabilized and the inmunofluorescence was performed and analyzed as reported (Pendas-Franco et al., 2007) . As primary and secondary antibodies, we used a monoclonal anti-b tubulin antibody (Sigma) and Alexa 488 donkey anti-mouse (Jackson ImmunoResearch, Cambridgeshire, UK).
In vitro migration and invasion Cells were seeded on 8.0 mm. pore Transwells (Corning Incorporated, Corning, NY, USA) previously covered either with 0.5% gelatin for migration assays or with Matrigel matrix (125 mg/ml; BD Biosciences, Bedford, MA, USA) for invasion assays. HMVEC were starved for 16 h before adding the CM. After 24 h incubation, cells attached to the lower surface of the filter were stained using Diff-Quik reagents (Dade Behring, Newark, DE, USA) and counted (10 fields/Transwell). Transfections with small interfering RNAs (siRNAs) were performed following the manufacturer's instructions and 24 h later either the cells were trypsinized and seeded on Transwells to assay their migration capacity or changed into serum-free medium. In this case, after 48 h, CM were collected and used for HMVEC migration assays. DKK-4 and control siRNAs were from Dharmacon (Lafayette, CO, USA). Recombinant human DKK-4 protein was from R&D Systems (Minneapolis, MN, USA).
In vitro formation of capillary-like tubules HMVEC (25 Â 10 3 ) were seeded in 96-well culture plates precoated with growth factor-reduced Matrigel (pure or diluted 1:2 (v/v) in cell culture medium) and exposed to CM from either control or DKK-4-expressing cells (30 mg/ml) for either 4 h (pure Matrigel) or 48 h (1:2 diluted Matrigel). Tubule formation was filmed on a digital camera attached to an inverted microscope.
